Contact
Please use this form to send email to PR contact of this press release:
InterveXion Announces Positive Results from Pre-Specified Interim Review of Phase 2 STAMPOUT Study
TO:
Misty Stevens
InterveXion Therapeutics
+1 501-554-2377